NexImmune Statistics
Total Valuation
NexImmune has a market cap or net worth of $3.40 million. The enterprise value is -$1.07 million.
| Market Cap | 3.40M |
| Enterprise Value | -1.07M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NexImmune has 1.37 million shares outstanding. The number of shares has increased by 19.88% in one year.
| Shares Outstanding | 1.37M |
| Shares Change (YoY) | +19.88% |
| Shares Change (QoQ) | +17.56% |
| Owned by Insiders (%) | 21.95% |
| Owned by Institutions (%) | 11.66% |
| Float | 1.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.24 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.30, with zero debt.
| Current Ratio | 1.30 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -328.20% and return on invested capital (ROIC) is -944.58%.
| Return on Equity (ROE) | -328.20% |
| Return on Assets (ROA) | -186.00% |
| Return on Capital (ROIC) | -944.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.31M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.62% in the last 52 weeks. The beta is 1.98, so NexImmune's price volatility has been higher than the market average.
| Beta (5Y) | 1.98 |
| 52-Week Price Change | -64.62% |
| 50-Day Moving Average | 3.13 |
| 200-Day Moving Average | 4.79 |
| Relative Strength Index (RSI) | 31.53 |
| Average Volume (20 Days) | 8,598 |
Short Selling Information
The latest short interest is 16,621, so 1.21% of the outstanding shares have been sold short.
| Short Interest | 16,621 |
| Short Previous Month | 12,317 |
| Short % of Shares Out | 1.21% |
| Short % of Float | 1.44% |
| Short Ratio (days to cover) | 1.95 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -25.91M |
| Pretax Income | -25.86M |
| Net Income | -25.86M |
| EBITDA | -24.53M |
| EBIT | -25.86M |
| Earnings Per Share (EPS) | -$24.10 |
Balance Sheet
The company has $4.47 million in cash and no debt, giving a net cash position of $4.47 million or $3.26 per share.
| Cash & Cash Equivalents | 4.47M |
| Total Debt | n/a |
| Net Cash | 4.47M |
| Net Cash Per Share | $3.26 |
| Equity (Book Value) | 2.74M |
| Book Value Per Share | 2.00 |
| Working Capital | 1.41M |
Cash Flow
In the last 12 months, operating cash flow was -$21.56 million and capital expenditures $520,783, giving a free cash flow of -$21.04 million.
| Operating Cash Flow | -21.56M |
| Capital Expenditures | 520,783 |
| Free Cash Flow | -21.04M |
| FCF Per Share | -$16.83 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NexImmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.88% |
| Shareholder Yield | -19.88% |
| Earnings Yield | -760.44% |
| FCF Yield | -618.82% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on October 19, 2023. It was a reverse split with a ratio of 1:25.
| Last Split Date | Oct 19, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |